BR112022004170A2 - Peptídeo curto, conjugado, vacina para prevenir ou tratar a aterosclerose, usos e método de prevenção ou tratamento da aterosclerose - Google Patents

Peptídeo curto, conjugado, vacina para prevenir ou tratar a aterosclerose, usos e método de prevenção ou tratamento da aterosclerose

Info

Publication number
BR112022004170A2
BR112022004170A2 BR112022004170A BR112022004170A BR112022004170A2 BR 112022004170 A2 BR112022004170 A2 BR 112022004170A2 BR 112022004170 A BR112022004170 A BR 112022004170A BR 112022004170 A BR112022004170 A BR 112022004170A BR 112022004170 A2 BR112022004170 A2 BR 112022004170A2
Authority
BR
Brazil
Prior art keywords
atherosclerosis
short peptide
seq
amino acid
acid sequence
Prior art date
Application number
BR112022004170A
Other languages
English (en)
Inventor
Chenfeng Mao
Jingang Zheng
Wei Kong
Xiao Chen
Yi Fu
Yuhua Liao
Zihan Ma
Original Assignee
Beijing Kimway Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Kimway Biotech Co Ltd filed Critical Beijing Kimway Biotech Co Ltd
Publication of BR112022004170A2 publication Critical patent/BR112022004170A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24082—ADAMTS-4 endopeptidase (3.4.24.82), i.e. aggrecanase 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/30—Animals modified by surgical methods
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

peptídeo curto, conjugado, vacina para prevenir ou tratar a aterosclerose, usos e método de prevenção ou tratamento da aterosclerose. a presente invenção divulga fragmentos peptídicos imunogênicos da metaloprotease adamts-7 e usos dos mesmos na antiaterosclerose e doenças relacionadas. a presente invenção primeiramente divulga um peptídeo curto, que é qualquer um dos seguintes: um peptídeo curto possuindo a sequência de aminoácidos apresentada na seq id no: 1 na listagem de sequências; um peptídeo curto possuindo a sequência de aminoácidos apresentada na seq id no: 2 na listagem de sequências; um peptídeo curto possuindo a sequência de aminoácidos apresentada na seq id no: 3 na listagem de sequências; um peptídeo curto possuindo a sequência de aminoácidos apresentada na seq id no: 4 na listagem de sequências. a presente invenção divulga ainda o uso de conjugados contendo os peptídeos curtos referidos acima e vacinas contendo os referidos conjugados. as vacinas contendo os peptídeos curtos da presente invenção podem inibir de maneira notável a neogênese da íntima em modelos de camundongos de reestenose vascular e a ocorrência de aterosclerose em camundongos alimentados com alto teor de gordura e podem ser usadas para a prevenção ou tratamento da aterosclerose e/ou reestenose vascular.
BR112022004170A 2019-09-25 2020-08-20 Peptídeo curto, conjugado, vacina para prevenir ou tratar a aterosclerose, usos e método de prevenção ou tratamento da aterosclerose BR112022004170A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910914243.9A CN112553184B (zh) 2019-09-25 2019-09-25 金属蛋白酶adamts-7的免疫原性肽段及其在抗动脉粥样硬化及相关疾病的应用
PCT/CN2020/110233 WO2021057346A1 (zh) 2019-09-25 2020-08-20 金属蛋白酶adamts-7的免疫原性肽段及其在抗动脉粥样硬化及相关疾病的应用

Publications (1)

Publication Number Publication Date
BR112022004170A2 true BR112022004170A2 (pt) 2022-05-31

Family

ID=75029540

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022004170A BR112022004170A2 (pt) 2019-09-25 2020-08-20 Peptídeo curto, conjugado, vacina para prevenir ou tratar a aterosclerose, usos e método de prevenção ou tratamento da aterosclerose

Country Status (9)

Country Link
US (1) US20220370578A1 (pt)
EP (1) EP4019545A4 (pt)
JP (1) JP2022549579A (pt)
KR (1) KR20220088410A (pt)
CN (1) CN112553184B (pt)
AU (1) AU2020355080A1 (pt)
BR (1) BR112022004170A2 (pt)
CA (1) CA3155665A1 (pt)
WO (1) WO2021057346A1 (pt)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1737973A1 (en) * 2004-04-16 2007-01-03 Wyeth Truncated adamts molecules
US20080268473A1 (en) * 2005-02-17 2008-10-30 Moses Marsha A Adamts-7 as a Biomarker for Cancers of Epithelial Origin
CN101294158B (zh) * 2008-06-06 2010-09-15 北京大学 一种抑制血管内膜增生的小分子干扰rna
CN103071152B (zh) * 2012-11-03 2018-02-23 中国医学科学院医学生物学研究所 动脉粥样硬化疫苗

Also Published As

Publication number Publication date
KR20220088410A (ko) 2022-06-27
WO2021057346A1 (zh) 2021-04-01
CN112553184A (zh) 2021-03-26
AU2020355080A1 (en) 2022-04-14
CA3155665A1 (en) 2021-04-01
CN112553184B (zh) 2021-08-03
EP4019545A4 (en) 2022-11-16
JP2022549579A (ja) 2022-11-28
US20220370578A1 (en) 2022-11-24
EP4019545A1 (en) 2022-06-29

Similar Documents

Publication Publication Date Title
BR112022014808A2 (pt) Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2
BRPI0610093A2 (pt) composiÇço farmacÊutica, e, mÉtodo para prevenir ou tratar uma doenÇa associada com os depàsitos de amilàides de alfa-beta no cÉrebro de um paciente
BRPI0607326A2 (pt) composição de vacina, variante de peptìdeo de survivina, uso da referida composição, kit em partes e medicamento
BR0108924A (pt) Composição umonogênica adaptada para administração a um hospedeiro humano para o tratamento ou prevenção da aterosclerose, vacina, e, método de tratamento ou profilaxia da aterosclerose
BR0011000A (pt) Métodos para prevenir ou tratar uma doença associada com depósitos amilóides de ab no cérebro de um paciente, para avaliar um anticorpo quanto á atividade de remoção de uma entidade biológica fisicamente associada com um antìgeno e para detectara um depósito amilóide em um paciente, composição farmacêutica, e, conjunto de diagnóstico
BR112012018951A8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
HRP20110386T1 (hr) Sintetička sekvenca mecp2 za zamjensku proteinsku terapiju
BR112017019343A2 (pt) uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas
BRPI0510016B8 (pt) vetor lentiviral recombinante, composição imunogênica e uso dos mesmos como vacina
BR112022005687A2 (pt) Vacinas contra o hbv e métodos para tratar o hbv
BR112022007595A2 (pt) Métodos para tratar doença de alzheimer
BR112018007960A2 (pt) conjugado, proteína pcrv, composição imunogênica, métodos de preparação de uma composição imunogênica, de tratamento e de produção de um bioconjugado, polinucleotídeo, vetor, célula hospedeira, e, bioconjugado.
JP2015500827A5 (pt)
BR112022004058A2 (pt) Conjugados, populações de conjugados, composição farmacêutica, métodos para o tratamento de um sujeito com uma infecção viral, o tratamento profilático de uma infecção viral, para prevenir uma infecção secundária e para tratar ou prevenir uma infecção viral
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
BR112022007158A2 (pt) Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico
BR112022005757A2 (pt) Uricase aperfeiçoada e método de tratamento de hiperuricemia usando a mesma
BR112017010238A2 (pt) composições e métodos para prevenir ou tratar doenças, condições ou processos caracterizados por proliferação de fibroblastos e a deposição aberrante de matriz extracelular
PE20230171A1 (es) Vacunas contra el coronavirus y metodos de uso
BR112022017189A2 (pt) Métodos de tratamento de glomeruloesclerose segmentar focal dependente de apol-1
MX2017008994A (es) Formulacion de peptidos inhibidores mk2.
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
BR112019011350A2 (pt) terapia de combinação
MX2023012368A (es) Vacuna de virus.